EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseVergleichsstudie

Comparative efficacy of biologic agents for severe chronic rhinosinusitis with nasal polyps: Systematic review and network meta-analysis

Konstantinos Ouranos, Mark Michael, Evangelia K Mylona, Sophia C Mylonakis, Akash Guruswamy, Fadi Shehadeh, Tina Motazedi, David P Huston

Journal of Allergy and Clinical Immunology · 2026

DOI: 10.1016/j.jaci.2026.06.016 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026. Verfasst von Konstantinos Ouranos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Charles W. Duncan Jr Department of Medicine, Houston Methodist Hospital, Houston, Tex. Hauptthemen laut MEDLINE: Rhinosinusitis, Nasal Polyps, Biological Factors, Sinusitis. Die Arbeit nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Biologic therapies improve outcomes in severe chronic rhinosinusitis with nasal polyps (CRSwNP), but their comparative efficacy remains uncertain. OBJECTIVE: We compared the efficacy and safety of 7 biologic agents (dupilumab, omalizumab, mepolizumab, benralizumab, depemokimab, tezepelumab, and stapokibart) for the treatment of severe CRSwNP. METHODS: We systematically reviewed randomized trials in PubMed and EMBASE evaluating biologic agents for severe CRSwNP. Primary outcomes were changes in nasal polyp score (NPS) and nasal congestion score (NCS) at 20-24 and 48-56 weeks. Secondary outcomes included changes in loss-of-smell test, 22-item Sinonasal Outcome Test, University of Pennsylvania Smell Identification Test, Lund-Mackay scores, need for nasal polyp surgery or systemic corticosteroids, and safety. We used mean differences and odds ratios with 95% confidence intervals for analysis. RESULTS: Fifteen randomized trials involving 3,642 patients were included. At 20-24 weeks, dupilumab and stapokibart produced greater reductions in NPS and NCS compared to depemokimab, omalizumab, and benralizumab, with no significant differences between dupilumab and stapokibart for NPS (mean difference [95% confidence interval]: 0.29 [-0.97, 0.40]) and NCS (0.19 [-0.03, 0.42]). At 48-56 weeks, dupilumab and tezepelumab produced greater reductions in NPS and NCS than depemokimab, mepolizumab, or benralizumab; no significant differences were observed between dupilumab and tezepelumab for NPS (0.32 [-0.17, 0.81]) and NCS (0.06 [-0.19, 0.31]). Dupilumab, tezepelumab (at 48-56 weeks only), and stapokibart (at 20-24 weeks only) showed superior outcomes for secondary end points against other tested biologics. Safety profiles were comparable across agents. CONCLUSION: Dupilumab, tezepelumab, and stapokibart were associated with greater clinical benefit than other biologics in severe CRSwNP. Indirect comparisons did not demonstrate superiority of stapokibart (at 20-24 weeks) or tezepelumab (at 48-56 weeks) over dupilumab, highlighting the need for direct comparative trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhinosinusitisNasal PolypsBiological FactorsSinusitisRhinitisHumansChronic DiseaseTreatment OutcomeRandomized Controlled Trials as TopicAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

CRSwNPchronic rhinosinusitis with nasal polypsdupilumabstapokibarttezepelumab

Substanzen

Biological FactorsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Charles W. Duncan Jr Department of Medicine, Houston Methodist Hospital, Houston, Tex.
  • Charles W. Duncan Jr Department of Medicine, Houston Methodist Hospital, Houston, Tex; School of Rural, Surveying and Geoinformatics Engineering, National Technical University of Athens, Athens, Greece.
  • Charles W. Duncan Jr Department of Medicine, Houston Methodist Hospital, Houston, Tex; School of Electrical and Computer Engineering, National Technical University of Athens, Athens, Greece.
  • Division of Allergy and Immunology, Immunology Center, Charles W. Duncan Jr. Department of Medicine, Houston Methodist Hospital, Houston, Tex.
  • Division of Allergy and Immunology, Immunology Center, Charles W. Duncan Jr. Department of Medicine, Houston Methodist Hospital, Houston, Tex; Naresh K. Vashisht College of Medicine, Texas A&M University, Houston, Tex.…

Zitieren

APA

Ouranos, K., Michael, M., Mylona, E. K., Mylonakis, S. C., Guruswamy, A., Shehadeh, F., Motazedi, T., & Huston, D. P. (2026). Comparative efficacy of biologic agents for severe chronic rhinosinusitis with nasal polyps: Systematic review and network meta-analysis. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2026.06.016

Vancouver

Ouranos K, Michael M, Mylona EK, Mylonakis SC, Guruswamy A, Shehadeh F, et al. Comparative efficacy of biologic agents for severe chronic rhinosinusitis with nasal polyps: Systematic review and network meta-analysis. Journal of Allergy and Clinical Immunology. 2026. doi:10.1016/j.jaci.2026.06.016

BibTeX
@article{Ouranos2026,
  author = {Ouranos, Konstantinos and Michael, Mark and Mylona, Evangelia K and Mylonakis, Sophia C and Guruswamy, Akash and Shehadeh, Fadi and Motazedi, Tina and Huston, David P},
  title = {Comparative efficacy of biologic agents for severe chronic rhinosinusitis with nasal polyps: Systematic review and network meta-analysis},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2026},
  doi = {10.1016/j.jaci.2026.06.016}
}
Kostenlos starten →